Monoamine transporter structure, Function, Dynamics, and Drug discovery: A computational perspective

AAPS Journal

Volumn 14, Issue 4, 2012, Pages 820-831

  Manepalli, Sankar ^a   Surratt, Christopher K ^a   Madura, Jeffry D ^a   Nolan, Tammy L ^a  

^a DUQUESNE UNIVERSITY   (United States)

Author keywords

Homology model; Molecular dynamics; Monoamine transporter; Virtual screening

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CARRIER PROTEIN; DOPAMINE; DOPAMINE TRANSPORTER; IFENPRODIL DERIVATIVE; LEUCINE TRANSPORTER PROTEIN; MEMBRANE PROTEIN; MONOAMINE TRANSPORTER; NORADRENALIN; NORADRENALIN TRANSPORTER; PSYCHOSTIMULANT AGENT; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SODIUM SYMPORTER; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANXIETY; ATTENTION DEFICIT DISORDER; BINDING AFFINITY; BINDING SITE; COMPUTER SIMULATION; CRYSTAL STRUCTURE; CRYSTALLIZATION; DEPRESSION; DRUG DEPENDENCE; DRUG PROTEIN BINDING; DRUG RESEARCH; GENE MUTATION; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN STRUCTURE; PROTON TRANSPORT; REVIEW; SCHIZOPHRENIA; SEQUENCE ALIGNMENT; STRUCTURAL HOMOLOGY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THREE DIMENSIONAL IMAGING; VIRTUAL REALITY;

BACTERIAL PROTEINS; CRYSTALLIZATION; DOPAMINE; DRUG DISCOVERY; HUMANS; LEUCINE; MENTAL DISORDERS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; NEUROTRANSMITTER TRANSPORT PROTEINS; NOREPINEPHRINE; SEROTONIN;

EID: 84869124607     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9391-0     Document Type: Review

References (84)

1. Kristensen AS, Andersen J, Jorgensen TN, Sorensen L, Eriksen J, Loland CJ, et al. SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev. 2011;63 (3):585-640.
2. Hahn MK, Blakely RD. Monoamine transporter gene structure and polymorphisms in relation to psychiatric and other complex disorders. Pharmacogenomics J. 2002;2:217-35.
3. Heinz A, Mann K, Weinberger DR, Goldman D. Serotonergic dysfunction, negative mood states, and response to alcohol. Alcohol Clin Exp Res. 2001;25(4):487-95.
4. Klimek V, Stockmeier C, Overholser J, Meltzer HY, Kalka S, Dilley G, et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci. 1997;17 (21):8451-8.
5. Miller GM, De La Garza II R, Novak MA, Madras BK. Single nucleotide polymorphisms distinguish multiple dopamine transporter alleles in primates: Implications for association with attention deficit hyperactivity disorder and other neuropsychiatric disorders. Mol Psychiatry. 2001;6(1):50-8.
6. Ozaki N, Goldman D, Kaye WH, Greenberg BD, Lappalainen J, Rudnick G, et al. Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol Psychiatry. 2003;8:933-6.
7. Robertson D, Flattem N, Tellioglu T, Carson R, Garland E, Shannon JR, et al. Familial orthostatic tachycardia due to norepinephrine transporter deficiency. Ann N Y Acad Sci. 2001;940:527-43.
8. Yamashita A, Singh SK, Kawate T, Jin Y, Gouaux E. Crystal structure of a bacterial homologue of Na+/Cl-dependent neurotransmitter transporters. Nature. 2005;437(7056):215-23.
9. Brust A, Palant E, Croker DE, Colless B, Drinkwater R, Patterson B, et al. ?-Conopeptide pharmacophore development: toward a novel class of norepinephrine transporter inhibitor (Xen2174) for pain. J Med Chem. 2009;52(22):6991-7002.
10. Chen C, Dyck B, Fleck BA, Foster AC, Grey J, Jovic F, et al. Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008;18(4):1346-9.
11. Enyedy IJ, Sakamuri S, Zaman WA, Johnson KM, Wang S. Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors. Bioorg Med Chem Lett. 2003;13(3):513-7.
12. Enyedy IJ, Wang J, Zaman WA, Johnson KM, Wang S. Discovery of substituted 3,4-diphenyl-Thiazoles as a novel class of monoamine transporter inhibitors through 3-D pharmacophore search using a new pharmacophore model derived from mazindol. Bioorg Med Chem Lett. 2002;12:1775-8.
13. Enyedy IJ, Zaman WA, Sakamuri S, Kozikowski AP, Johnson KM, Wang S. Pharmacophore-based discovery of 3,4-disubstituted pyrrolidines as a novel class of monoamine transporter inhibitors. Bioorg Med Chem Lett. 2001;11(9):1113-8.
14. Macdougall IJ, Griffith R. Pharmacophore design and database searching for selective monoamine neurotransmitter transporter ligands. J Mol Graph Model. 2008;26(7):1113-24.
15. Pratuangdejkul J, Schneider B, Jaudon P, Rosilio V, Baudoin E, Loric S, et al. Definition of an uptake pharmacophore of the serotonin transporter through 3D-QSAR analysis. Curr Med Chem. 2005;12(20):2393-410.
16. Pratuangdejkul J, Schneider B, Launay JM, Kellermann O, Manivet P. Computational approaches for the study of serotonin and its membrane transporter SERT: implications for drug design in neurological sciences. Curr Med Chem. 2008;15 (30):3214-27.
17. Wang S, Sakamuri S, Enyedy IJ, Kozikowski AP, Deschaux O, Bandyopadhyay BC, et al. Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-Activity relationships, and behavioral pharmacological studies. J Med Chem. 2000;43(3):351-60.
18. Edvardsen O, Dahl SG. A putative model of the dopamine transporter. Brain Res Mol Brain Res. 1994;27:265-74.
19. Ravna A, Edvardsen O. A putative three-dimensional arrangement of the human serotonin transporter transmembrane helices: a tool to aid experimental studies. J Mol Graph Model. 2001;20:133-44.
20. Ravna A, Sylte I, Kristiansen K, Dahl S. Putative drug binding conformations of monoamine transporters. Bioorg Med Chem. 2006;14(3):666-75.
21. Ravna AW. Three-dimensional models of neurotransmitter transporters and their interactions with cocaine and S-citalopram. World J Biol Psychiatry. 2006;7:99-109.
22. Ravna AW, Sylte I, Dahl SG. Molecular model of the neural dopamine transporter. J Comput Aided Mol Des. 2003;17:367-82.
23. Guan L, Kaback HR. Lessons from lactose permease. Annu Rev Biophys Biomol Struct. 2006;35:67-91.
24. Beuming T, Shi L, Javitch JA, Weinstein H. A comprehensive structure-based alignment of prokaryotic and eukaryotic neurotransmitter/Na+ symporters (NSS) aids in the use of the LeuT structure to probe NSS structure and function. Mol Pharm. 2006;70(5):1630-42.
25. Rudnick G. Cytoplasmic permeation pathway of neurotransmitter transporters. Biochemistry. 2011;50(35):7462-75.
26. Shi L, Quick M, Zhao Y, Weinstein H, Javitch JA. The mechanism of a neurotransmitter:sodium symporter-inward release of Na+ and substrate is triggered by substrate in a second binding site. Mol Cell. 2008;30(6):667-77.
27. Koldso H, Noer P, Grouleff J, Autzen HE, Sinning S, Schiott B. Unbiased simulations reveal the inward-facing conformation of the human serotonin transporter and Na ion release. PLoS Comput Biol. 2011;7(10). doi:10.1371/journal.pcbi.1002246.
28. Huang X, Gu HH, Zhan CG. Mechanism for cocaine blocking the transport of dopamine: insights from molecular modeling and dynamics simulations. J Phys Chem. 2009;113:15057-66.
29. Zhou Z, Zhen J, Karpowich NK, Law CJ, Reith ME, Wang DN. Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nat Struct Mol Biol. 2009;16 (6):652-7.
30. Paczkowski FA, Sharpe IA, Dutertre S, Lewis RJ. X-conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model. J Biol Chem. 2007;282(24):17837-44.
31. Jorgensen AM, Tagmose L, Bogeso KP, Peters GH. Molecular dynamics simulations of Na+/Cl(-)-dependent neurotransmitter transporters in a membrane-Aqueous system. ChemMedChem. 2007;2(6):827-40.
32. Andersen J, Olsen L, Hansen KB, Taboureau O, Jorgensen FS, Jorgensen AM, et al. Mutational mapping and modeling of the binding site for (S)-citalopramin the human serotonin transporter. J Biol Chem. 2010;285(3):2051-63.
33. Andersen J, Taboureau O, Hansen KB, Olsen L, Egebjerg J, Stromgaard K, et al. Location of the antidepressant binding site in the serotonin transporter: importance of Ser-438 in recognition of citalopram and tricyclic antidepressants. J Biol Chem. 2009;284(15):10276-84.
34. Andersen J, Stuhr-Hansen N, Zachariassen L, Toubro S, Hansen SM, Eildal JN, et al. Molecular determinants for selective recognition of antidepressants in the human serotonin and norepinephrine transporters. Proc Natl Acad Sci U S A. 2011;108(29):12137-42.
35. Kaufmann KW, Dawson ES, Henry LK, Field JR, Blakely RD, Meiler J. Structural determinants of species-selective substrate recognition in human and Drosophila serotonin transporters revealed through computational docking studies. Proteins. 2009;74(3):630-42.
36. Henry LK, Iwamoto H, Field JR, Kaufmann K, Dawson ES, Jacobs MT, et al. A conserved asparagine residue in transmembrane segment 1 (TM1) of serotonin transporter dictates chloride-coupled neurotransmitter transport. J Biol Chem. 2011;286(35):30823-36.
37. Enyedy IJ, Ling Y, Nacro K, Tomita Y, Wu X, Cao Y, et al. Discovery of small-molecule inhibitors of Bcl-2 through structurebased computer screening. J Med Chem. 2001;44(25):4313-24.
38. Xhaard H, Backstrom V, Denessiouk K, Johnson MS. Coordination of Na(+) by monoamine ligands in dopamine, norepinephrine, and serotonin transporters. J Chem Inf Model. 2008;48 (7):1423-37.
39. Wang W, Sonders MS, Ukairo OT, Scott H, Kloetzel MK, Surratt CK. Dissociation of high-Affinity cocaine analog binding and dopamine uptake inhibition at the dopamine transporter. Mol Pharmacol. 2003;64(2):430-9.
40. Zhou Z, Zhen J, Karpowich NK, Goetz RM, Law CJ, Reith MEA, et al. LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science. 2007;317 (5843):1390-3.
41. Mitchell P. Osmochemistry of solute translocation. Res Microbiol. 1990;141:286-9.
42. Gabrielsen M, Ravna AW, Kristiansen K, Sylte I. Substrate binding and translocation of the serotonin transporter studied by docking and molecular dynamics simulations. J Mol Model. 2011. doi:10.1007/s00894-011-1133-1.
43. Quick M, Lund Winther A-M, Shi L, Nissen P, Weinstein H, Javitch JA. Binding of an octylglucoside detergent molecule in the second substrate (S2) site of LeuT establishes an inhibitorbound conformation. Proc Natl Acad Sci U S A. 2009;106 (14):5563-8.
44. Singh SK, Yamashita A, Gouaux E. Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. Nature. 2007;448(7156):952-6.
45. Forrest LR, Tavoulari S, Zhang YW, Rudnick G, Honig B. Identification of a chloride ion binding site in Na+/Cl-dependent transporters. Proc Natl Acad Sci U S A. 2007;104(31):12761-6.
46. Tavoulari S, Rizwan AN, Forrest LR, Rudnick G. Reconstructing a chloride-binding site in a bacterial neurotransmitter transporter homologue. J Biol Chem. 2011;286(4):2834-42.
47. Sucic S, Dallinger S, Zdrazil B, Weissensteiner R, Jorgensen TN, Holy M, et al. The N terminus of monoamine transporters is a lever required for the action of amphetamines. J Biol Chem. 2010;285(14):10924-38.
48. Manepalli S, Geffert LM, Surratt CK, Madura JD. Discovery of novel selective serotonin reuptake inhibitors through development of a protein-based pharmacophore. J Chem Inf Model. 2011;51 (9):2417-26.
49. Irwin JJ, Shoichet BK. ZINC-A free database of commercially available compounds for virtual screening. J Chem Inf Model. 2005;45(1):177-82.
50. Schlessinger A, Geier E, Fan H, Irwin JJ, Shoichet BK, Giacomini KM, et al. Struture-based discovery of prescription drugs that interact with the norepinephrine transporter, NET. Proc Natl Acad Sci U S A. 2011;108(38):15810-5.
51. Huang X, Zhan C. How dopamine transporter interacts with dopamine: insights from molecular modeling and simulation. Biophys J. 2007;93(10):3627-39.
52. Indarte M, Madura JD, Surratt CK. Dopamine transporter comparative molecular modeling and binding site prediction using the LeuTAa leucine transporter as a template. Proteins Struct Funct Bioinforma. 2008;70(3):1033-46.
53. Zhao Y, Terry DS, Shi L, Quick M, Weinstein H, Blanchard SC, et al. Substrate-modulated gating dynamics in a Na(+)-coupled neurotransmitter transporter homologue. Nature. 2011;474 (7349):109-13.
54. Piscitelli CL, Krishnamurthy H, Gouaux E. Neurotransmitter/sodium symporter orthologue LeuT has a single high-Affinity substrate site. Nature. 2010;468(7327):1129-32.
55. Hill ER, Huang X, Zhan CG, Carroll FI, Gu HH. Interaction of tyrosine 151 in norepinephrine transporter with the 2-ß group of cocaine analogRTI-113. Neuropharmacology. 2011;61(1-2):112-20.
56. Singh SK, Piscitelli CL, Yamashita A, Gouaux E. A competitive inhibitor traps LeuT in an open-To-out conformation. Science. 2008;322(5908):1655-61.
57. Ravna AW, Jaronczyk M, Sylte I. A homology model of SERT based on the LeuT(Aa) template. Bioorg Med Chem Lett. 2006;16(21):5594-7.
58. Henry LK, Defelice LJ, Blakely RD. Getting the message across: a recent transporter structure shows the way. Neuron. 2006;49 (6):791-6.
59. Celik L, Sinning S, Severinsen K, Hansen CG, MollerMS, Bols M, et al. Binding of serotonin to the human serotonin transporter. Molecular modeling and experimental validation. J Am Chem Soc. 2008;130(12):3853-65.
60. Jorgensen AM, Tagmose L, Topiol S, Sabio M, Gundertofte K, Bogeso KP, et al. Homology modeling of the serotonin transporter: insights into the primary escitalopram-binding site. ChemMedChem. 2007;2(6):815-26.
61. Indarte M, Madura JD, Surratt CK, editors. Comparative molecular modeling of the dopamine transporter using the leucine transporter LeuTAa as a template. Atlanta: Society for Neuroscience; 2006.
62. Beuming T, Kniazeff J, Bergmann ML, Shi L, Gracia L, Raniszewska K, et al. The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci. 2008;11(7):780-9.
63. Bisgaard H, Larsen MA, Mazier S, Beuming T, Newman AH, Weinstein H, et al. The binding sites for benztropines and dopamine in the dopamine transporter overlap. Neuropharmacology. 2011;60(1):182-90.
64. Schmitt KC, Mamidyala S, Biswas S, Dutta AK, Reith ME. Bivalent phenethylamines as novel dopamine transporter inhibitors: evidence for multiple substrate-binding sites in a single transporter. J Neurochem. 2010;112(6):1605-18.
65. Ravna AW, Sylte I, Dahl SG. Structure and localisation of drug binding sites on neurotransmitter transporters. J Mol Model. 2009;15(10):1155-64.
66. Sarker S, Weissensteiner R, Steiner I, Sitte HH, Ecker GF, Freissmuth M, et al. The high-Affinity binding site for tricyclic antidepressants resides in the outer vestibule of the serotonin transporter. Mol Pharmacol. 2010;78(6):1026-35.
67. Zomot E, Bendahan A, Quick M, Zhao Y, Javitch JA, Kanner BI. Mechanism of chloride interaction with neurotransmitter: sodium symporters. Nature. 2007;449(7163):726-30.
68. Gedeon PC, Indarte M, Surratt CK, Madura JD. Molecular dynamics of leucine and dopamine transporter proteins in a model cell membrane lipid bilayer. Proteins Struct Funct Bioinforma. 2010;78(4):797-811.
69. Shan J, Javitch JA, Shi L, Weinstein H. The substrate-driven transition to an inward-facing conformation in the functional mechanism of the dopamine transporter. PLoS One. 2011;6(1). doi:10.1371/journal.pone.0016350.
70. Guptaroy B, Zhang M, Bowton E, Binda F, Shi L, Weinstein H, et al. A juxtamembrane mutation in the N terminus of the dopamine transporter induces preference for an inward-facing conformation. Mol Pharmacol. 2009;75(3):514-24.
71. Krishnamurthy H, Gouaux E. X-ray structures of LeuT in substrate-free outward-open and apo inward-open states. Nature. 2012;481(7382):469-74.
72. Jaronczyk M, Chilmonczyk Z, Mazurek AP, Nowak G, Ravna AW, Kristiansen K, et al. The molecular interactions of buspirone analogues with the serotonin transporter. Bioorg Med Chem. 2008;16(20):9283-94.
73. Wenthur CJ, Rodriguez GJ, Kuntz CP, Barker EL. Conformational flexibility of transmembrane helix VII of the human serotonin transporter impacts ion dependence and transport. Biochem Pharmacol. 2010;80(9):1418-26.
74. Indarte M, Liu Y, Madura JD, Surratt CK. Receptor-based discovery of a plasmalemmal monoamine transporter inhibitor via high throughput docking and pharmacophore modeling. ACS Chem Neurosci. 2010;1(3):223-33.
75. Nolan TL, Lapinsky DJ, Talbot JN, Indarte M, Liu Y, Manepalli S, et al. Identification of a novel selective serotonin reuptake inhibitor by coupling monoamine transporter-based virtual screening and rational molecular hybridization. ACS Chem Neurosci. 2011;2(9):544-52.
76. Okuda S, Yamada T, Hamajima M, Itoh M, Katayama T, Bork P, et al. KEGG Atlas mapping for global analysis of metabolic pathways. Nucleic Acids Res. 2008;36:W423-6.
77. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003;300(5626):1763-7.
78. Enyedy IJ, Lee S-L, Kuo AH, Dickson RB, Lin C-Y, Wang S. Structure-based approach for the discovery of Bis-benzamidines as novel inhibitors of matriptase. J Med Chem. 2001;44(9):1349-55.
79. Li R, Chen X, Gong B, Selzer PM, Li Z, Davidson E, et al. Structure-based design of parasitic protease inhibitors. Bioorg Med Chem. 1996;4(9):1421-7.
80. Que X, Brinen LS, Perkins P, Herdman S, Hirata K, Torian BE, et al. Cysteine proteinases from distinct cellular compartments are recruited to phagocytic vesicles by Entamoeba histolytica. Mol Biochem Parasitol. 2002;119(1):23-32.
81. Rajnarayanan RV, Dakshanamurthy S, Pattabiraman N. Teaching old drugs to kill new bugs: structure-based discovery of anti-SARS drugs. Biochem Biophys Res Commun. 2004;321(2):370-8.
82. Selzer PM, ChenX, ChanVJ, ChengM,KenyonGL, Kuntz ID, et al. Leishmania major: molecular modeling of cysteine proteases and prediction of new nonpeptide inhibitors. Exp Parasitol. 1997;87 (3):212-21.
83. Zuccotto F, Zvelebil M, Brun R, Chowdhury SF, Di Lucrezia R, Leal I, et al. Novel inhibitors of Trypanosoma cruzi dihydrofolate reductase. Eur J Med Chem. 2001;36(5):395-405.
84. Schlessinger A, Matsson P, Shima JE, Pieper U, Yee SW, Kelly L, et al. Comparison of human solute carriers. Prot Sci. 2010;19 (3):412-28.